Acute and Subclinical Myocardial Injury in COVID-19

Coronavirus disease 2019 (COVID-19) is a global pandemic that, at the time of this writing, has led to 178,000,000 cases worldwide and more than 3,875,000 deaths. Cardiovascular complications of COVID-19 have become the focus of investigation after many hospitalized COVID-19 patients—with or without...

Descripción completa

Detalles Bibliográficos
Autores principales: Crudo, Valentina L., Ahmed, Ahmed I., Cowan, Eilidh L., Shah, Dipan J., Al-Mallah, Mouaz H., Malahfji, Maan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Houston Methodist DeBakey Heart & Vascular Center 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680173/
https://www.ncbi.nlm.nih.gov/pubmed/34992721
http://dx.doi.org/10.14797/mdcvj.1038
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is a global pandemic that, at the time of this writing, has led to 178,000,000 cases worldwide and more than 3,875,000 deaths. Cardiovascular complications of COVID-19 have become the focus of investigation after many hospitalized COVID-19 patients—with or without established cardiovascular disease—incurred clinical or subclinical myocardial injury, including isolated biomarker elevations, myocardial infarction, arrhythmia, heart failure, myocarditis, and cardiogenic shock. In this review, we highlight the most recent evidence of the prevalence and potential etiologies of acute and subclinical myocardial injury in COVID-19 patients.

Ejemplares similares